← 返回前沿论文

儿童胶质瘤的免疫挑战与免疫治疗进展

英文原题:Pediatric gliomas immunity challenges and immunotherapy advances.

PubMed 2025/03/14(内容时间) Cancer Lett Q1 · IF 11.8(JCR 2025)

研究概要

儿童胶质瘤是儿童中最常见的脑肿瘤,其特征是异质性和独特的肿瘤免疫微环境。

中文摘要

儿童胶质瘤是儿童中最常见的脑肿瘤,其特征是异质性和独特的肿瘤免疫微环境。它们被分为不同的亚型,包括毛细胞星形细胞瘤等低级别胶质瘤,以及弥漫性中线胶质瘤和弥漫性内生性桥脑胶质瘤等高级别胶质瘤,每种亚型都表现出不同的免疫学特征。儿童胶质瘤的肿瘤免疫微环境由细胞和非细胞成分塑造,包括免疫细胞、细胞因子和细胞外基质,参与肿瘤进展、免疫逃逸和治疗反应。儿童低级别胶质瘤通常表现为免疫抑制性微环境,而高级别胶质瘤则以复杂的免疫浸润和错综复杂的免疫抑制机制为特征。血脑屏障进一步阻碍了免疫细胞募集和治疗递送。尽管在理解成人胶质瘤方面取得了进展,但儿童肿瘤的免疫生物学研究甚少,关于胶质瘤细胞与T细胞、NK 细胞以及肿瘤相关巨噬细胞等免疫群体之间相互作用的数据有限。在此,我们提供关于儿童胶质瘤肿瘤免疫微环境相互作用当前知识的最新进展,重点介绍免疫抑制机制以及旨在克服这些障碍以改善受影响儿童临床结局的新兴免疫治疗策略。

展开英文摘要原文

Pediatric gliomas, the most frequent brain tumors in children, are characterized by heterogeneity and a unique tumor immune microenvironment. They are categorized into different subtypes, including low-grade gliomas like pilocytic astrocytomas and high-grade gliomas such as diffuse midline gliomas and diffuse intrinsic pontine gliomas, each exhibiting distinct immunological profiles. The tumor immune microenvironment in pediatric gliomas is shaped by cellular and non-cellular components, including immune cells, cytokines, and the extracellular matrix, involved in tumor progression, immune evasion, and response to therapy. While pediatric low-grade gliomas often display an immunosuppressed microenvironment, high-grade gliomas are characterized by complex immune infiltrates and intricate immunosuppressive mechanisms. The blood-brain barrier further obscures immune cell recruitment and therapeutic delivery. Despite advances in understanding adult gliomas, the immunobiology of pediatric tumors is poorly investigated, with limited data on the interactions between glioma cells and immune populations such as T and natural killer cells, as well as tumor-associated macrophages. Herein, we provide an update of the current knowledge on tumor immune microenvironment interactions in pediatric gliomas, highlighting the immunosuppressive mechanisms and emerging immunotherapeutic strategies aiming at overcoming these barriers to improve clinical outcomes for affected children.

论文信息

作者
Vetsika EK、Katsianou MA、Sarantis P、Palamaris K、Papavassiliou AG、Piperi C
第一作者单位
Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.Greece
通讯作者单位
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: cpiperi@med.uoa.gr.Greece
文献类型
综述
期刊
Cancer letters2025 May 28
原文标识
PubMed 40090572 · DOI 10.1016/j.canlet.2025.217640